Journal
PSYCHIATRY RESEARCH
Volume 239, Issue -, Pages 281-283Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.psychres.2016.03.034
Keywords
Esketamine; Parvalbumin; R-ketamine
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology, Japan [24116006]
- Uehara Memorial Foundation (Tokyo, Japan)
- Japan Society for the Promotion of Science (Tokyo, Japan)
- Grants-in-Aid for Scientific Research [16J00514, 24116006] Funding Source: KAKEN
Ask authors/readers for more resources
Clinical use of the rapid antidepressant drug ketamine is limited, due to psychotomimetic side effects. R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to S-ketamine (esketamine), since it is free of psychotomimetic side effects. Repeated, intermittent administration of esketamine (10 mg/kg, once per week for 8-weeks), but not R-ketamine, caused loss of parvalbumin (PV)-immunoreactivity in the medial prefrontal cortex and hippocampus of mouse brains, regions associated with psychosis. This study suggests that repeated intermittent use of R-ketamine is safer than esketamine in the treatment of depression. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available